Hims & Hers Health has leveraged regulatory loopholes to sell weight-loss drugs quickly, benefitting from the rising popularity of such treatments while bypassing extensive clinical trials.
The company's stock surged over the past year and a half due to its discounted weight-loss drugs, but recently suffered a 43% decline as Eli Lilly announced similar products at lower prices.
Eli Lilly's entry into the market with FDA-approved weight-loss drugs shakes the foundation of Hims & Hers' competitive advantage, pushing the company's stock prices down significantly.
In the past two years, weight-loss drugs have garnered enormous attention and economic success, with leading products like Wegovy generating billions in sales and transforming market dynamics.
Collection
[
|
...
]